Sberro-Soussan Rebecca, Zuber Julien, Suberbielle-Boissel Caroline, Legendre Christophe
Université Paris Descartes, Paris, France.
Clin Transpl. 2009:433-8.
In renal transplant recipients, the persistence of donor specific anti-HLA antibodies (DSA) associated with antibody-mediated graft injuries predicts evolution toward chronic humoral rejection and lower graft survival. Targeting plasma cells with the proteasome inhibitor bortezomib may be a promising desensitization strategy. We evaluated the in vivo efficacy of one cycle of bortezomib (1.3 mg/m2 x 4 doses), used as the sole desensitization therapy, in four renal transplant recipients experiencing sub-acute antibody-mediated rejection with persisting DSA (>2000 [Mean Fluorescence Intensity] MFI). Bortezomib treatment did not significantly decrease DSA MFI within the 270-day post-treatment period in any patient. In conclusion, one cycle of bortezomib alone does not decrease DSA levels in sensitized kidney transplant recipients.
在肾移植受者中，与抗体介导的移植物损伤相关的供体特异性抗HLA抗体（DSA）持续存在预示着会发展为慢性体液排斥反应，并降低移植物存活率。使用蛋白酶体抑制剂硼替佐米靶向浆细胞可能是一种有前景的脱敏策略。我们评估了在4例经历亚急性抗体介导排斥反应且DSA持续存在（平均荧光强度[MFI]>2000）的肾移植受者中，将一个疗程的硼替佐米（1.3mg/m²，共4剂）用作唯一脱敏治疗的体内疗效。在任何患者中，硼替佐米治疗在治疗后的270天内均未显著降低DSA的MFI。总之，单独一个疗程的硼替佐米不会降低致敏肾移植受者的DSA水平。
